Enhertu approved in China for previously treated patients with HER2+ metastatic Solid tumors

Enhertu approved in China for HER2-positive early Breast cancer with residual disease

ELAHERE approved in Japan for patients with FRα-positive, platinum-resistant recurrent Ovarian cancer

Enhertu plus pertuzumab approved in the EU for the 1st-line treatment of patients with HER2-positive...

Trodelvy expanded to 1L metastatic TNBC Across PD-L1 Status in the EU

Novartis’ Pluvicto receives approval in China for a new indication

Enhertu with Pertuzumab approved in China for 1L HER2-positive metastatic Breast cancer

Hengrui’s Aiweida receives NMPA approval for HER2-positive Colorectal cancer

AbbVie’s Elahere receives Minzdrav approval in Russia for Ovarian, Fallopian tube and Peritoneal cancer